Norfenazin (Nortriptyline Hydrochloride)

Nortriptyline Hydrochloride, the active ingredient in Norfenazin, is a tricyclic antidepressant presented as an oral tablet for oral use. It is prescribed for major depressive disorder, neuropathic pain and chronic tension‑type headache in adult patients. The medication works by modulating neurotransmitter levels, thereby improving mood and reducing pain perception.

GNH USA supplies Norfenazin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality and regulatory compliance.

Norfenazin (nortriptyline hydrochloride) is used in several therapeutic areas that involve mood regulation and pain modulation. - Major depressive disorder: alleviates depressive symptoms and improves mood in adults. - Neuropathic pain: reduces pain intensity associated with diabetic neuropathy or post‑herpetic neuralgia. - Chronic tension‑type headache: decreases frequency and severity of tension‑type headache episodes.

Norfenazin may cause a range of adverse reactions, which are grouped by frequency and clinical significance.

Common Side Effects: - Dry mouth: reduced salivary secretion causing discomfort. - Drowsiness or sedation: increased sleepiness. - Constipation: slowed gastrointestinal motility. - Blurred vision: temporary visual disturbances. - Weight gain: modest increase in body weight. - Orthostatic hypotension: light‑headedness upon standing.

Serious or Rare Side Effects: - Cardiac arrhythmias: irregular heart rhythm, especially in overdose. - Seizures: risk of convulsive episodes. - Severe hypotension: marked drop in blood pressure. - Hepatotoxicity: liver enzyme elevation or injury. - Serotonin syndrome: potentially life‑threatening condition when combined with serotonergic agents. - Agranulocytosis: marked reduction in white blood cells.

Before prescribing Norfenazin, clinicians should consider several safety measures and patient‑specific factors. - Cardiac assessment: evaluate history of heart disease or conduction abnormalities. - Age considerations: use lower initial doses in elderly patients due to increased sensitivity. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression. - Suicide risk: assess for worsening depression or suicidal thoughts, especially early in therapy. - Pregnancy and lactation: avoid unless benefit outweighs potential risk; discuss with obstetrician. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Norfenazin can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension or serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: increased serotonin syndrome risk. - Anticholinergic drugs: additive anticholinergic burden leading to severe dry mouth, constipation, urinary retention. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): raise nortriptyline plasma levels, risk of toxicity. - Drugs that prolong QT interval: may precipitate cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CNS depressants (benzodiazepines, alcohol): enhanced sedation and respiratory depression. - Antihypertensives: additive hypotensive effect, monitor blood pressure. - Diuretics: potential for electrolyte imbalance, especially potassium loss. - Anticonvulsants (carbamazepine, phenytoin): may reduce nortriptyline levels, decreasing efficacy. - NSAIDs: increased risk of gastrointestinal bleeding.